ALN-PNP vs ARO-PNPLA3
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: PNPLA3 · full MASH / NASH pipeline
ALN-PNP
Developed by Alnylam Pharmaceuticals and partners
NCT06024408 · Phase 1 · completed
Participants were randomly assigned and neither they nor the study staff knew who received ALN-PNP versus placebo, which is a solid design. But only 9 people were enrolled and the trial's own findings have not yet been posted, so there is no result to judge yet. Its registered primary outcome on ClinicalTrials.gov is "Incidence of treatment-emergent adverse events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: August 2027 · NCT05648214 (registry estimate)
No aligned efficacy figure on record for this race.
ARO-PNPLA3
Developed by Madrigal Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALN-PNP | ARO-PNPLA3 |
|---|---|---|
| MASH resolution without fibrosis worsening | —Not reported | —Not reported |
| Fibrosis stage, change | —Not reported | —Not reported |
| Liver fat (MRI-PDFF), change | —Not reported | —Not reported |
| ALT, change | —Not reported | —Not reported |
MASH resolution without fibrosis worsening
- ALN-PNP
- —Not reported
- ARO-PNPLA3
- —Not reported
Fibrosis stage, change
- ALN-PNP
- —Not reported
- ARO-PNPLA3
- —Not reported
Liver fat (MRI-PDFF), change
- ALN-PNP
- —Not reported
- ARO-PNPLA3
- —Not reported
ALT, change
- ALN-PNP
- —Not reported
- ARO-PNPLA3
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALN-PNP: no structured comparison results are available for MASH / NASH.
ARO-PNPLA3: no structured comparison results are available for MASH / NASH.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALN-PNP's landscape · ARO-PNPLA3's landscape